Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Axsome Therapeutics (NASDAQ:AXSM) has received diverse analyst ratings over the last three months, with a current average 12-month price target of $131.89, reflecting a 6.52% increase from the previous average of $123.82. The company, a clinical-stage biopharmaceutical focused on CNS disorders, has shown a revenue growth of 193.5% as of December 31, 2023, but struggles with profitability and operational efficiency, indicated by a net margin of -137.92% and ROE of -42.85%.
April 29, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics has received a range of analyst ratings, with a notable increase in its 12-month price target to $131.89. The company's significant revenue growth contrasts with its profitability challenges.
The increase in the average 12-month price target suggests a positive outlook from analysts, which could lead to increased investor confidence and potentially drive up the stock price in the short term. However, the company's profitability issues, as indicated by negative net margin and ROE, may temper investor enthusiasm. The significant revenue growth indicates potential, but operational efficiencies need to be addressed for long-term success.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100